Rosanna Tedesco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rosanna Tedesco has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
Dashyant Dhanak
Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
5 shared publications- Kevin J. Duffya
GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, and Ligand Pharmaceuticals, 10275 Science Center Drive, San Diego, California 92121
5 shared publications Michael G. Darcy
Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
5 shared publicationsDeping Chai
Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
4 shared publicationsDuke M. Fitch
Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
4 shared publicationsElio Napolitano
Dipartimento di Chimica Bioorganica, Università di Pisa, Via Bonanno 33, 56126 Pisa, Italy
4 shared publications
Latest Publications
- 20 January 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (3) , 217-222
Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors
A novel series of potent and selective hexokinase 2 (HK2) inhibitors, 2,6-disubstituted glucosamines, has been identified based on HTS hits, exemplified by compound 1. Inhibitor-bound crystal structures revealed that the HK2 enzyme could adopt an “induced-fit” conformation. The SAR study led to the identification of potent HK2 inhibitors, such as compound 34 with greater than 100-fold selectivity over HK1. Compound 25 inhibits in situ glycolysis in a UM-UC-3 bladder tumor cell line via 13CNMR measurement of [3-13C]lactate produced from [1,6-13C2]glucose added to the cell culture.
- 20 January 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (3) , 217-222
Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors
A novel series of potent and selective hexokinase 2 (HK2) inhibitors, 2,6-disubstituted glucosamines, has been identified based on HTS hits, exemplified by compound 1. Inhibitor-bound crystal structures revealed that the HK2 enzyme could adopt an “induced-fit” conformation. The SAR study led to the identification of potent HK2 inhibitors, such as compound 34 with greater than 100-fold selectivity over HK1. Compound 25 inhibits in situ glycolysis in a UM-UC-3 bladder tumor cell line via 13CNMR measurement of [3-13C]lactate produced from [1,6-13C2]glucose added to the cell culture.
- 12 June 2012
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 3 (7) , 524-529
Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors
A novel thiazolopyrimidinone series of PI3K-beta selective inhibitors has been identified. This chemotype has provided an excellent tool compound, 18, that showed potent growth inhibition in the PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage-independent conditions, and it also demonstrated pharmacodynamic effects and efficacy in a PTEN-deficient prostate cancer PC-3 xenograft mouse model.
- 12 June 2012
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 3 (7) , 524-529
Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors
A novel thiazolopyrimidinone series of PI3K-beta selective inhibitors has been identified. This chemotype has provided an excellent tool compound, 18, that showed potent growth inhibition in the PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage-independent conditions, and it also demonstrated pharmacodynamic effects and efficacy in a PTEN-deficient prostate cancer PC-3 xenograft mouse model.
- 19 January 2010
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 1 (1) , 30-34
Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295
Inhibition of mitotic kinesins represents a novel approach for the discovery of a new generation of anti-mitotic cancer chemotherapeutics. We report here the discovery of the first potent and selective inhibitor of centromere-associated protein E (CENP-E) 3-chloro-N-{(1S)-2-[(N,N-dimethylglycyl)amino]-1-[(4-{8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl}phenyl)methyl]ethyl}-4-[(1-methylethyl)oxy]benzamide (GSK923295; 1), starting from a high-throughput screening hit, 3-chloro-4-isopropoxybenzoic acid 2. Compound 1 has demonstrated broad antitumor activity in vivo and is currently in human clinical trials.
- 19 January 2010
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 1 (1) , 30-34
Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295
Inhibition of mitotic kinesins represents a novel approach for the discovery of a new generation of anti-mitotic cancer chemotherapeutics. We report here the discovery of the first potent and selective inhibitor of centromere-associated protein E (CENP-E) 3-chloro-N-{(1S)-2-[(N,N-dimethylglycyl)amino]-1-[(4-{8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl}phenyl)methyl]ethyl}-4-[(1-methylethyl)oxy]benzamide (GSK923295; 1), starting from a high-throughput screening hit, 3-chloro-4-isopropoxybenzoic acid 2. Compound 1 has demonstrated broad antitumor activity in vivo and is currently in human clinical trials.
- 1 August 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (15) , 4350-4353
Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase
- 1 August 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (15) , 4350-4353
Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase
- 10 January 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (3) , 971-983
3-(1,1-Dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, Potent Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase
Recently, we disclosed a new class of HCV polymerase inhibitors discovered through high-throughput screening (HTS) of the GlaxoSmithKline proprietary compound collection. This interesting class of 3-(1,1-dioxo-2H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones potently inhibits HCV polymerase enzymatic activity and inhibits the ability of the subgenomic HCV replicon to replicate in Huh-7 cells. This report will focus on the structure−activity relationships (SAR) of substituents on the quinolinone ring, culminating in the discovery of 1-(2-cyclopropylethyl)-3-(1,1-dioxo-2H-1,2,4-benzothiadiazin-3-yl)-6-fluoro-4-hydroxy-2(1H)-quinolinone (130), an inhibitor with excellent potency in biochemical and cellular assays possessing attractive molecular properties for advancement as a clinical candidate. The potential for development and safety assessment profile of compound 130 will also be discussed.
- 10 January 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (3) , 971-983
3-(1,1-Dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, Potent Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase
Recently, we disclosed a new class of HCV polymerase inhibitors discovered through high-throughput screening (HTS) of the GlaxoSmithKline proprietary compound collection. This interesting class of 3-(1,1-dioxo-2H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones potently inhibits HCV polymerase enzymatic activity and inhibits the ability of the subgenomic HCV replicon to replicate in Huh-7 cells. This report will focus on the structure−activity relationships (SAR) of substituents on the quinolinone ring, culminating in the discovery of 1-(2-cyclopropylethyl)-3-(1,1-dioxo-2H-1,2,4-benzothiadiazin-3-yl)-6-fluoro-4-hydroxy-2(1H)-quinolinone (130), an inhibitor with excellent potency in biochemical and cellular assays possessing attractive molecular properties for advancement as a clinical candidate. The potential for development and safety assessment profile of compound 130 will also be discussed.
- Open Access
- 1 May 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (19) , 16602-16607
Arresting Initiation of Hepatitis C Virus RNA Synthesis Using Heterocyclic Derivatives
- 1 May 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (19) , 16602-16607
Open AccessArresting Initiation of Hepatitis C Virus RNA Synthesis Using Heterocyclic Derivatives
- 1 May 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (10) , 1281-1284
Synthesis and evaluation of hexahydrochrysene and tetrahydrobenzofluorene ligands for the estrogen receptor
- 1 May 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (10) , 1281-1284
Synthesis and evaluation of hexahydrochrysene and tetrahydrobenzofluorene ligands for the estrogen receptor